Perampanel for Patients Aged 12 Years and Older
Perampanel is FDA-approved for patients aged 12 years and older as adjunctive therapy for partial-onset seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures, with a starting dose of 2 mg once daily at bedtime, titrated by 2 mg weekly to a maintenance dose of 8-12 mg/day, but carries a boxed warning for serious psychiatric and behavioral reactions including aggression, hostility, and homicidal ideation. 1
Indications
Perampanel is indicated for:
- Partial-onset seizures (with or without secondary generalization) in patients ≥4 years of age 1
- Primary generalized tonic-clonic seizures as adjunctive therapy in patients ≥12 years of age 1
The drug is a first-in-class non-competitive AMPA glutamate receptor antagonist 1, 2, representing a unique mechanism of action among antiepileptic medications.
Dosing Regimen
Standard Dosing (Without CYP3A4 Inducers)
Starting dose: 2 mg once daily at bedtime 1
Titration: Increase by 2 mg increments weekly based on clinical response and tolerability 1
Maintenance doses:
- Partial-onset seizures: 8-12 mg once daily at bedtime 1
- Primary generalized tonic-clonic seizures: 8 mg once daily at bedtime 1
The drug exhibits a half-life of approximately 105 hours, allowing once-daily dosing 1, 3. It is rapidly absorbed with near-complete bioavailability (~100%) and reaches maximum concentration in 0.5-2.5 hours 4.
Dosing with CYP3A4 Inducers
When co-administered with moderate or strong CYP3A4 inducers (carbamazepine, oxcarbazepine, phenytoin, eslicarbazepine), perampanel clearance increases significantly 1:
- Carbamazepine reduces perampanel AUC by 64-67% 1
- Oxcarbazepine reduces AUC by 48% 1
- Phenytoin reduces AUC by 43% 1
Higher doses are required when these inducers are present, and close monitoring is necessary when they are introduced or withdrawn 1.
Special Population Dosing
Hepatic impairment:
- Mild impairment: Maximum 6 mg/day 1
- Moderate impairment: Maximum 4 mg/day 1
- Severe impairment: Not recommended 1
Perampanel exposure increases 1.8-fold in mild and 3.3-fold in moderate hepatic impairment, with prolonged half-life (295-306 hours vs. 125-139 hours in controls) 1.
Renal impairment:
- Mild impairment: No adjustment needed (though AUC increases 37%) 1
- Severe impairment or hemodialysis: Not recommended 1
Elderly patients: Increase dose no more frequently than every 2 weeks 1
Contraindications
None listed 1
However, the drug is not recommended in severe hepatic impairment, severe renal impairment, or patients on hemodialysis 1.
Adverse Effects
Common Adverse Effects (≥5% and >1% higher than placebo)
The most frequent adverse effects are 1, 5:
- Dizziness (most common)
- Somnolence
- Fatigue
- Irritability
- Falls
- Nausea
- Weight gain (>7% increase in 14.6% vs. 7.1% placebo) 5
- Vertigo
- Ataxia
- Headache
- Vomiting
- Contusion
- Abdominal pain
- Anxiety
These effects are dose-dependent, with higher incidence at 12 mg doses 5, 4.
Serious Psychiatric and Behavioral Reactions (Boxed Warning)
Critical warning: Perampanel carries a boxed warning for serious or life-threatening psychiatric and behavioral reactions 1:
- Aggression
- Hostility
- Irritability
- Anger
- Homicidal ideation and threats
Management approach:
- Monitor closely during titration and at higher doses 1
- Reduce dose if symptoms occur 1
- Discontinue immediately if symptoms are severe or worsening 1
Depression and aggression were reported more frequently than placebo, particularly at higher doses 5. The rate of serious psychiatric adverse events was low overall, but vigilance is essential 5.
Other Important Safety Concerns
Suicidal behavior and ideation: Monitor for suicidal thoughts or behavior 1
Neurologic effects: Dizziness, gait disturbance, somnolence, and fatigue require caution when driving or operating machinery 1
Falls: Monitor for falls and injuries 1
DRESS/Multi-organ hypersensitivity: Discontinue if no alternate etiology identified 1
Withdrawal seizures: In patients with epilepsy, abrupt discontinuation may increase seizure frequency 1
Treatment discontinuation: In clinical trials, 9.5% of perampanel patients withdrew due to adverse events (vs. 4.8% placebo), typically due to dizziness, convulsion, and somnolence 5. Most adverse events were mild to moderate in intensity 5.
Drug Interactions
Hormonal contraceptives: Perampanel 12 mg once daily may decrease effectiveness of levonorgestrel-containing contraceptives 1
CYP3A4 inducers: As detailed above, carbamazepine, oxcarbazepine, phenytoin, and eslicarbazepine significantly reduce perampanel levels, requiring dose adjustment 1
Clinical Efficacy
Perampanel demonstrates robust efficacy in drug-resistant epilepsy 4, 6:
Partial-onset seizures:
- Median seizure reduction: 23% (4 mg), 26-31% (8 mg), 18-35% (12 mg) vs. 10-21% (placebo) 4
- 50% responder rates: 29% (4 mg), 33-38% (8 mg), 34-36% (12 mg) vs. 15-26% (placebo) 4
- Seizure freedom: 2.6-6.5% (12 mg) vs. 0-1.7% (placebo) 4
Primary generalized tonic-clonic seizures:
- Median seizure reduction: 76.5% vs. 38.4% (placebo) 4
- 50% responder rate: 64.2% vs. 39.5% (placebo) 4
- Seizure freedom during maintenance: 30.9% vs. 12.3% (placebo) 4
Sustained seizure control has been demonstrated for up to 4 years in extension studies 6.
Key Clinical Pearls
- Bedtime dosing is recommended to minimize CNS side effects 1
- Slow titration (weekly increments) maximizes tolerability 3
- The drug requires no dose adjustment based on sex, race, or age alone (except elderly) 1
- Oral suspension (0.5 mg/mL) is available and should be measured using the provided adapter and dosing syringe 1
- Perampanel is highly protein-bound (~95%) and undergoes extensive hepatic metabolism via CYP3A4 4